Public neoantigens in breast cancer immunotherapy (Review)
- Authors:
- Natthaporn Sueangoen
- Peti Thuwajit
- Pa-Thai Yenchitsomanus
- Chanitra Thuwajit
-
Affiliations: Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand, Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE‑CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand - Published online on: June 17, 2024 https://doi.org/10.3892/ijmm.2024.5388
- Article Number: 65
-
Copyright: © Sueangoen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC and Ahrendt GM: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Cancer. 116:1431–1439. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 534:47–54. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pon JR and Marra MA: Driver and passenger mutations in cancer. Annu Rev Pathol. 10:25–50. 2015. View Article : Google Scholar | |
|
Chen T, Wang Z, Zhou W, Chong Z, Meric-Bernstam F, Mills GB and Chen K: Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics. 17(Suppl 2): S3942016. View Article : Google Scholar | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li CI, Uribe DJ and Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 93:1046–1052. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Caswell-Jin JL, Lorenz C and Curtis C: Molecular heterogeneity and evolution in breast cancer. Annu Rev Cancer Biol. 5:79–94. 2021. View Article : Google Scholar | |
|
Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysal SD, et al: A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 177:1330–1345.e18. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tsang JYS and Tse GM: Molecular classification of breast cancer. Adv Anat Pathol. 27:27–35. 2020. View Article : Google Scholar | |
|
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Chen Z, Su K and Zeng J: Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 8:8500–8505. 2015.PubMed/NCBI | |
|
Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO and Perou CM: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar | |
|
Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi F, et al: Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 16:R652014. View Article : Google Scholar : PubMed/NCBI | |
|
Tang P and Tse GM: Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update. Arch Pathol Lab Med. 140:806–814. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN and Giordano SH: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol. 28:92–98. 2010. View Article : Google Scholar : | |
|
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al: Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 24:157–167. 2011. View Article : Google Scholar | |
|
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M: Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 24(Suppl 2): S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, et al: Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:691–722. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, et al: Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European organisation for research and treatment of cancer randomized phase III trial 10853-A study by the EORTC breast cancer cooperative group and EORTC radiotherapy group. J Clin Oncol. 24:3381–3387. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, et al: RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 33:709–715. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H and Emdin S: Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 26:1247–1252. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bhushan A, Gonsalves A and Menon JU: Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics. 13:7232021. View Article : Google Scholar : PubMed/NCBI | |
|
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, et al: Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet. 381:1827–1834. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rodon J, Braña I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, et al: Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs. 32:670–681. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, et al: Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 17:811–821. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schneble E, Jinga DC and Peoples G: Breast cancer immunotherapy. Maedica (Bucur). 10:185–191. 2015.PubMed/NCBI | |
|
Kang C and Syed YY: Atezolizumab (in combination with nab-paclitaxel): A review in advanced triple-negative breast cancer. Drugs. 80:601–607. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 28:1099–1105. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hu ZI, Ho AY and McArthur HL: Combined radiation therapy and immune checkpoint blockade therapy for breast cancer. Int J Radiat Oncol Biol Phys. 99:153–164. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P and Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 12:337–365. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Butterfield LH: Cancer vaccines. BMJ. 350:h9882015. View Article : Google Scholar : PubMed/NCBI | |
|
Perica K, Varela JC, Oelke M and Schneck J: Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 6:e00042015. View Article : Google Scholar : PubMed/NCBI | |
|
Ilyas S and Yang JC: Landscape of tumor antigens in T cell immunotherapy. J Immunol. 195:5117–5122. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Srinivasan R and Wolchok JD: Tumor antigens for cancer immunotherapy: Therapeutic potential of xenogeneic DNA vaccines. J Transl Med. 2:122004. View Article : Google Scholar : PubMed/NCBI | |
|
Benvenuto M, Focaccetti C, Izzi V, Masuelli L, Modesti A and Bei R: Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Semin Cancer Biol. 72:65–75. 2021. View Article : Google Scholar | |
|
Alatrash G, Crain AK and Molldrem JJ: Chapter 7-tumor-associated antigens. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Socié G, Zeiser R and Blazar BR: 2nd edition. Academic Press; pp. 107–125. 2019, View Article : Google Scholar | |
|
Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, et al: Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 130:1985–1994. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL and Papamichail M: HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer. 98:864–872. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zhenjiang L, Rao M, Luo X, Sandberg E, Bartek J Jr, Schoutrop E, von Landenberg A, Meng Q, Valentini D, Poiret T, et al: Mesothelin-specific immune responses predict survival of patients with brain metastasis. EBioMedicine. 23:20–24. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC and Romero P: High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 190:705–716. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, et al: Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 30:5091–5097. 2010.PubMed/NCBI | |
|
Parvanova I, Rettig L, Knuth A and Pascolo S: The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine. 29:3832–3836. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mohsenzadegan M, Razmi M, Vafaei S, Abolhasani M, Madjd Z, Saeednejad Zanjani L and Sharifi L: Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer. Sci Rep. 12:5992022. View Article : Google Scholar : PubMed/NCBI | |
|
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH and Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499:214–218. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Makkouk A and Weiner GJ: Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar | |
|
Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, Miklosi AG, Johal H, Bastos RN, Huang K, et al: Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 23:562024. View Article : Google Scholar : PubMed/NCBI | |
|
Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 23:741–750. 2005. View Article : Google Scholar | |
|
Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH and Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1281–1284. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F and Franceschi S: Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health. 4:e609–e616. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al: Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 386:2078–2088. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Castle JC, Uduman M, Pabla S, Stein RB and Buell JS: mutation-derived neoantigens for cancer immunotherapy. Front Immunol. 10:18562019. View Article : Google Scholar : PubMed/NCBI | |
|
Capietto AH, Hoshyar R and Delamarre L: Sources of cancer neoantigens beyond single-nucleotide variants. Int J Mol Sci. 23:101312022. View Article : Google Scholar : PubMed/NCBI | |
|
Roudko V, Bozkus CC, Orfanelli T, McClain CB, Carr C, O'Donnell T, Chakraborty L, Samstein R, Huang KL, Blank SV, et al: Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 183:1634–1649.e17. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L, et al: Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 25:767–775. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Colditz GA, Kaphingst KA, Hankinson SE and Rosner B: Family history and risk of breast cancer: Nurses' health study. Breast Cancer Res Treat. 133:1097–1104. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Couch FJ, Nathanson KL and Offit K: Two decades after BRCA: Setting paradigms in personalized cancer care and prevention. Science. 343:1466–1470. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Narod SA and Foulkes WD: BRCA1 and BRCA2: 1994 And beyond. Nat Rev Cancer. 4:665–676. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Roy R, Chun J and Powell SN: BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer. 12:68–78. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Russo A, Calò V, Agnese V, Bruno L, Corsale S, Augello C, Gargano G, Barbera F, Cascio S, Intrivici C, et al: BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): A mutation analyses. Breast Cancer Res Treat. 105:267–276. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Armstrong N, Ryder S, Forbes C, Ross J and Quek RG: A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 11:543–561. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Metcalfe KA, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch HT, Karlan B, Foulkes WD, Singer CF, Neuhausen SL, et al: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. Clin Genet. 93:1063–1068. 2018. View Article : Google Scholar | |
|
Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sun K, Luo J, Guo J, Yao X, Jing X and Guo F: The PI3K/AKT/mTOR signaling pathway in osteoarthritis: A narrative review. Osteoarthritis Cartilage. 28:400–409. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A and Rugo HS: PIK3CA mutation status, progression and survival in advanced HR + /HER2-breast cancer: A meta-analysis of published clinical trials. BMC Cancer. 22:10022022. View Article : Google Scholar | |
|
Tonnessen-Murray CA, Lozano G and Jackson JG: The regulation of cellular functions by the p53 protein: Cellular senescence. Cold Spring Harb Perspect Med. 7:a0261122017. View Article : Google Scholar | |
|
Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C and Soussi T: The UMD TP53 database and website: Update and revisions. Hum Mutat. 27:14–20. 2006. View Article : Google Scholar | |
|
Ungerleider NA, Rao SG, Shahbandi A, Yee D, Niu T, Frey WD and Jackson JG: Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res. 20:1152018. View Article : Google Scholar : PubMed/NCBI | |
|
Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R and Ishioka C: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Soussi T and Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 1:233–240. 2001. View Article : Google Scholar | |
|
Parker MG, Arbuckle N, Dauvois S, Danielian P and White R: Structure and function of the estrogen receptor. Ann N Y Acad Sci. 684:119–126. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Pejerrey SM, Dustin D, Kim JA, Gu G, Rechoum Y and Fuqua SAW: The impact of ESR1 mutations on the treatment of metastatic breast cancer. Horm Cancer. 9:215–228. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jeselsohn R, Buchwalter G, De Angelis C, Brown M and Schiff R: ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 12:573–583. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, et al: Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer. Cell Rep. 24:1434–1444.e7. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Siddika T, Balasuriya N, Frederick MI, Rozik P, Heinemann IU and O'Donoghue P: Delivery of active AKT1 to human cells. Cells. 11:38342022. View Article : Google Scholar : PubMed/NCBI | |
|
George B, Gui B, Raguraman R, Paul AM, Nakshatri H, Pillai MR and Kumar R: AKT1 transcriptomic landscape in breast cancer cells. Cells. 11:22902022. View Article : Google Scholar : PubMed/NCBI | |
|
Keniry M and Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 27:5477–5485. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Sun J, Wang Q, Du Y, Cheng J, Yi J, Xie B, Jin S, Chen G, Wang L, et al: Systemic deficiency of PTEN accelerates breast cancer growth and metastasis. Front Oncol. 12:8254842022. View Article : Google Scholar : PubMed/NCBI | |
|
Sy SMH, Huen MSY, Zhu Y and Chen J: PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem. 284:18302–18310. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, et al: Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 371:497–506. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gao LB, Pan XM, Sun H, Wang X, Rao L, Li LJ, Liang WB, Lv ML, Yang WZ and Zhang L: The association between ATM D1853N polymorphism and breast cancer susceptibility: A meta-analysis. J Exp Clin Cancer Res. 29:1172010. View Article : Google Scholar : PubMed/NCBI | |
|
Apostolou P and Papasotiriou I: Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med Press). 9:331–335. 2017.PubMed/NCBI | |
|
Stewart GS, Wang B, Bignell CR, Taylor AMR and Elledge SJ: MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature. 421:961–966. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Patel AN, Goyal S, Wu H, Schiff D, Moran MS and Haffty BG: Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 126:601–607. 2011. View Article : Google Scholar | |
|
Liu C, Chang H, Li XH, Qi YF, Wang JO, Zhang Y and Yang XH: Network meta-analysis on the effects of DNA damage response-related gene mutations on overall survival of breast cancer based on TCGA database. J Cell Biochem. 118:4728–4734. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HS and Yang AS: Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer. 18:3152018. View Article : Google Scholar : PubMed/NCBI | |
|
Breast Cancer Association Consortium; Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, et al: Breast cancer risk genes-association analysis in more than 113,000 women. N Engl J Med. 384:428–439. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al: Signatures of mutational processes in human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ke L, Li S and Cui H: The prognostic role of tumor mutation burden on survival of breast cancer: A systematic review and meta-analysis. BMC Cancer. 22:11852022. View Article : Google Scholar : PubMed/NCBI | |
|
Narang P, Chen M, Sharma AA, Anderson KS and Wilson MA: The neoepitope landscape of breast cancer: Implications for immunotherapy. BMC Cancer. 19:2002019. View Article : Google Scholar : PubMed/NCBI | |
|
Stratton MR, Campbell PJ and Futreal PA: The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang G, Wang Y, Chen B, Guo L, Cao L, Ren C, Wen L, Li K, Jia M, Li C, et al: Characterization of frequently mutated cancer genes in Chinese breast tumors: A comparison of Chinese and TCGA cohorts. Ann Transl Med. 7:1792019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou S, Liu S, Zhao L and Sun HX: A comprehensive survey of genomic mutations in breast cancer reveals recurrent neoantigens as potential therapeutic targets. Front Oncol. 12:7864382022. View Article : Google Scholar : PubMed/NCBI | |
|
Carraro DM, Koike Folgueira MAA, Garcia Lisboa BC, Ribeiro Olivieri EH, Vitorino Krepischi AC, de Carvalho AF, de Carvalho Mota LD, Puga RD, do Socorro Maciel M, Michelli RA, et al: Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: A portrait of early-onset breast cancer in Brazil. PLoS One. 8:e575812013. View Article : Google Scholar : PubMed/NCBI | |
|
Kurian AW: BRCA1 and BRCA2 mutations across race and ethnicity: Distribution and clinical implications. Curr Opin Obstet Gynecol. 22:72–78. 2010. View Article : Google Scholar | |
|
Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, et al: Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 27:1532–1538. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, et al: Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 25:1526–1533. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM and Thomassen M: Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One. 8:e642682013. View Article : Google Scholar : PubMed/NCBI | |
|
De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, et al: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep. 10:70732020. View Article : Google Scholar : PubMed/NCBI | |
|
Linger RJ and Kruk PA: BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. FEBS J. 277:3086–3096. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lavoro A, Scalisi A, Candido S, Zanghì GN, Rizzo R, Gattuso G, Caruso G, Libra M and Falzone L: Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families. Int J Oncol. 60:582022. View Article : Google Scholar | |
|
Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, et al: Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol. 32:2951–2958. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Meyer DS, Brinkhaus H, Müller U, Müller M and Cardiff RD; mBentires-Alj M: Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res. 71:4344–4351. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al: COSMIC: Mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 39(Database Issue): D945–D950. 2011. View Article : Google Scholar : | |
|
Mangone FR, Bobrovnitchaia IG, Salaorni S, Manuli E and Nagai MA: PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo). 67:1285–1290. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Arsenic R, Treue D, Lehmann A, Hummel M, Dietel M, Denkert C and Budczies J: Comparison of targeted next-generation sequencing and sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol. 15:202015. View Article : Google Scholar : PubMed/NCBI | |
|
Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, Sanfeliu E, Schettini F, Conte B, Brasó-Maristany F, et al: Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 22:452020. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Chen X, Wen L, Wang Y, Chen B, Xue Y, Guo L and Liao N: Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA. Thorac Cancer. 11:1861–1868. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Behring M, Vazquez AI, Cui X, Irvin MR, Ojesina AI, Agarwal S, Manne U and Shrestha S: Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages. Mol Genet Genomic Med. 7:e10012019. View Article : Google Scholar : PubMed/NCBI | |
|
Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, et al: Mutation-derived neoantigen-specific T-cell responses in multiple myeloma. Clin Cancer Res. 26:450–464. 2020. View Article : Google Scholar | |
|
Walerych D, Napoli M, Collavin L and Del Sal G: The rebel angel: Mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 33:2007–2017. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, et al: The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology. 65:340–352. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Weis KE, Ekena K, Thomas JA, Lazennec G and Katzenellenbogen BS: Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol. 10:1388–1398. 1996.PubMed/NCBI | |
|
Zhang QX, Borg A, Wolf DM, Oesterreich S and Fuqua SA: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57:1244–1249. 1997.PubMed/NCBI | |
|
De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, et al: Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Ann Oncol. 25:1729–1735. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, et al: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45:1439–1445. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, et al: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 448:439–444. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R and Reischl J: AKT1 (E17K) mutation profiling in breast cancer: Prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer. 16:6222016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu W, Chen Y, Huang L, Li W, Tao C and Shen H: Effects of AKT1 E17K mutation hotspots on the biological behavior of breast cancer cells. Int J Clin Exp Pathol. 13:332–346. 2020.PubMed/NCBI | |
|
Xie R, Yan Z, Jing J, Wang Y, Zhang J, Li Y, Liu X, Yu X and Wu C: Functional defects of cancer-associated MDC1 mutations in DNA damage repair. DNA Repair (Amst). 114:1033302022. View Article : Google Scholar : PubMed/NCBI | |
|
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al: T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 375:2255–2262. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney SM and Wagle N: Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 31:387–394. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Meng X, Ruan X, Lu X, Yan F and Wang F: Characterization of neoantigen load subgroups in gynecologic and breast cancers. Front Bioeng Biotechnol. 8:7022020. View Article : Google Scholar : PubMed/NCBI | |
|
Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL and Griffith M: Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11:562019. View Article : Google Scholar : PubMed/NCBI | |
|
Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM, Mansfield AS, Block MS, Sherman ME, Knutson KL, et al: HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology. 9:17449472020. View Article : Google Scholar : PubMed/NCBI | |
|
Sahin U and Türeci Ö: Personalized vaccines for cancer immunotherapy. Science. 359:1355–1360. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, et al: Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9:1022–1035. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sueangoen N, Grove H, Chuangchot N, Prasopsiri J, Rungrotmongkol T, Sanachai K, Darai N, Thongchot S, Suriyaphol P, Sa-Nguanraksa D, et al: Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells. Cancer Immunol Immunother. 73:432024. View Article : Google Scholar : PubMed/NCBI | |
|
Jain KK: Personalized immuno-oncology. Med Princ Pract. 30:1–16. 2021. View Article : Google Scholar : | |
|
Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, et al: Breast cancer neoantigens can induce CD8+ T-cell responses and antitumor immunity. Cancer Immunol Res. 5:516–523. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xiuli Z, Goedegebuure SP, Myers NB, Vickery T, McLellan MD, Gao F, Sturmoski MA, Chen MY, Kim SW, Chen I, et al: Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer. medRxiv: 2021.2011.2019.21266466. 2021. | |
|
Disis MLN, Guthrie KA, Liu Y, Coveler AL, Higgins DM, Childs JS, Dang Y and Salazar LG: Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: A phase 1 nonrandomized clinical trial. JAMA Oncol. 9:71–78. 2023. View Article : Google Scholar | |
|
Morisaki T, Kubo M, Umebayashi M, Yew PY, Yoshimura S, Park JH, Kiyotani K, Kai M, Yamada M, Oda Y, et al: Neoantigens elicit T cell responses in breast cancer. Sci Rep. 11:135902021. View Article : Google Scholar : PubMed/NCBI | |
|
Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, et al: Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 34:155–163. 2016. View Article : Google Scholar : | |
|
Neefjes J, Jongsma ML, Paul P and Bakke O: Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 11:823–836. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Klebanoff CA and Wolchok JD: Shared cancer neoantigens: Making private matters public. J Exp Med. 215:5–7. 2018. View Article : Google Scholar : | |
|
Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, et al: Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 129:1109–1114. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pecher G, Häring A, Kaiser L and Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 51:669–673. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, et al: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 118:4354–4362. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ and Lord CJ: Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10:1475–1488. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ruangapirom L, Sutivijit N, Teerapakpinyo C, Mutirangura A and Doungkamchan C: Identification of shared neoantigens in BRCA1-related breast cancer. Vaccines (Basel). 10:15972022. View Article : Google Scholar : PubMed/NCBI | |
|
Iiizumi S, Ohtake J, Murakami N, Kouro T, Kawahara M, Isoda F, Hamana H, Kishi H, Nakamura N and Sasada T: Identification of novel HLA class II-restricted neoantigens derived from driver mutations. Cancers (Basel). 11:2662019. View Article : Google Scholar : PubMed/NCBI | |
|
Chandran SS, Ma J, Klatt MG, Dündar F, Bandlamudi C, Razavi P, Wen HY, Weigelt B, Zumbo P, Fu SN, et al: Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28:946–957. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lo W, Parkhurst M, Robbins PF, Tran E, Lu YC, Jia L, Gartner JJ, Pasetto A, Deniger D, Malekzadeh P, et al: Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res. 7:534–543. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, et al: Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 10:932–946. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, Hill VK, Li YF, Paria BC, Ray S, et al: Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol. 40:1741–1754. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
O'Connell MJ: Selection and the cell cycle: Positive Darwinian selection in a well-known DNA damage response pathway. J Mol Evol. 71:444–457. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Su YC, Lee WC, Wang CC, Yeh SA, Chen WH and Chen PJ: Targeting PI3K/AKT/mTOR signaling pathway as a radiosensitization in head and neck squamous cell carcinomas. Int J Mol Sci. 23:157492022. View Article : Google Scholar : PubMed/NCBI |
